BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase

Blood

Volumn 91, Issue 9, 1998, Pages 3156-3162

  De Fabritiis, Paolo ^a   Petti, Maria Concetta ^b   Montefusco, Enrico ^b   De Propris, Maria Stefania ^b   Sala, Roberta ^b   Bellucci, Roberto ^b   Mancini, Marco ^b   Lisci, Alessandro ^b   Bonetto, Francesco ^b   Geiser, Tim ^b   Calabretta, Bruno ^b   Mandelli, Franco ^b  

^a Institute of Hematology   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; BUSULFAN; MELPHALAN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TARGETING; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032079761     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3156     Document Type: Article

References (26)

1. Calabretta B: Inhibition of proto-oncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 51:4505, 1991
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93, 1984
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550, 1985
4. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 253:562, 1991
5. 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc Natl Acad USA 91:4504, 1994
6. Gewirtz AM, Luger S, Sokol D, Gowdin B, Stadtmauer E, Reccio A, Ratajczak MZ: Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results. Blood 88:l069a, 1996 (abstr, suppl 1)
7. Luger SM, Ratajczak MZ, Stadtmauer EA, Mangan P, Magee D, Silberstein L, Edelstein M, Nowell P, Gewirtz AM: Autografting for chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotide purged bone marrow: A preliminary report. Blood 84:591a, 1994 (abstr, suppl 1)
8. de Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent hematologic reconstitution after autologous bone marrow transplantation. Leukemia 9:662, 1995
9. de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukemia cells. Leukemia 11:811, 1997
10. Arnoldus EP, Wiegant J, Noordermeer IA, Wessels JW, Beverstock GC, Grosveld GC, Van-Der Ploeg M, Raap AK: Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet 54:108, 1990
11. de Fabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 12:261, 1993
12. Dhut S, Chaplin T, Young B: BCR-ABL and BCR proteins: Biochemical characterization and localization. Leukemia 4:745, 1990
13. Skorski T, Nieborwska-Skorska M, Wlodarski P, Zon G, lozzo RV, Calabretta B: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88:1005, 1996
14. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 359:67, 1992
15. Cohen JS, Hogan ME: The new genetic medicines. Sci Am 271:76, 1994
16. de Fabritiis P, Sandrelli A, Meloni G, Alimena G, Montefusco E, Lo Coco F, De Felice L, Mandelli F: Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting. Bone Marrow Transplant 6:247, 1990
17. Hoyle C, Gray R, Goldman JM: Autografting for patients with CML in chronic phase: An update. Br J Haematol 86:76, 1994
18. McGlave PB, de Fabritiis P, Deisseroth A, Goldman JM, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli A: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486, 1994
19. Reiffers J, Trouette R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou-Nabera C, Lacombe F: Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol 77:339, 1991
20. Meloni G, Pulsoni A, de Fabritiis P, Malagnino F, Montefusco E, Papa G, Sandrelli A, Simone F, Mandelli F: Autologous bone marrow transplantation (ABMT) for patients with chronic myelogenous leukemia (CML) in blastic phase (BP). Exp Hematol 13:47, 1985
21. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Lowenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alessandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606, 1990
22. de Fabritiis P, Calabretta B: Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukaemia: Are they still a promise? Haematologica 80:295, 1995
23. Chasty R, Whetton A, Lucas G: A comparison of the effect of bcr/abl breakpoint specific phosphorothioate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell population. Leuk Res 20:391, 1996
24. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM: Antisense bcr-abl oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156, 1994
25. O'Brien SG, Kirkland MA, Goldman JM: European School of Oncology Task Force Papers: Gene therapy-a future in cancer management? Antisense therapy for malignant disease. Eur J Cancer 30A: 1160, 1994
26. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to the inhibitory effect of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 88:2351, 1991